In this sense, it was possible to predict that the deficiency of or a reduction in the physiological function of ACE2 may favor pulmonary inflammation, thrombosis, obesity-induced hypertension, adipose tissue inflammation, and cardiac failure, which is especially detrimental to the baseline risk of COVID-19 patients (Figure 2). This evidence concerns the gene ACE2 and COVID-19.